Will we ever have effective treatments for dementia? Robert Howard King’s College London

Slides:



Advertisements
Similar presentations
Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which? Lockhart BP, Lestage PJ. January 2003.
Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Best Practices in Mental Health Services in Nursing Homes Steve Bartels, MD, MS President, American Association for Geriatric Psychiatry.
AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London.
Lucy Wang, M.D.. A 74 year old veteran with Alzheimer’s disease is referred for assistance in managing agitation. He is living in a nursing home, and.
Dementia Drugs: Mainstream and Alternative Medicines Susan Kurrle.
DEMENTIA JOE BEDFORD IBRAHIM ELSAFY ESCALIN PEIRIS.
Treatment Options for Dementia Deb Bynum, MD Division of Geriatric Medicine University of North Carolina.
A qualitative study exploring the CBT experience of dementia patients and their carers Mary Opoku (2012)
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Criteria for Psychiatric Symptoms in Alzheimer’s Disease Clinical Trials Jeffrey L. Cummings, M.D. Alzheimer’s Disease Center UCLA School of Medicine FDA.
Indianapolis Discovery Network for Dementia Translating PREVENT Into Your Practice Caring for your patients with dementia J. Eugene Lammers, MD, MPH Clarian.
Tracie Wymer Julie Franks Shirin Malek Inflammatory Diseases.
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
Risk of Developing Alzheimer’s Disease in Persons with MCI
Medication Therapies in the Treatment of Alzheimer’s Disease
Caring for People with Dementia in Primary Care: Diagnosis and Management Ngaire Kerse, John Scott, Michal Boyd.
Non-medication Management of Agitated Behavior in Dementia Patients Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology.
ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California Calabasas, California.
Best Practice Guide: Treatment and care for behavioural and psychological symptoms Clive Ballard, Anne Corbett, Alistair Burns Alzheimer’s Society UK.
Dementia Dr Deborah Stinson Sutton CMHT for Older People
Treatment of Parkinson’s Disease Dementia (PDD) Shanil Ebrahim.
Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.
Alzheimer’s Disease Landscape
Copyright © 2007, 2003 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 37 Confusion and Dementia.
Non-pharmacologic Management There is good evidence to recommend an individualized exercise program for patients with mild to moderate dementia – A simple.
LISA JOHNSON & SUZANNE GRIESEL MPH 543 LEADERSHIP AND ORGANIZATIONAL BEHAVIOR FEBRUARY 16, 2014 Funding Analysis of Alzheimer’s Treatment Options: Three.
Alzheimer’s Disease Causes, Effects, and Treatments.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Alzheimer’s Society, UK Our research programme
Why Physicians Do Not Diagnose Alzheimer’s Disease Mark A. Sager, MD Professor of Medicine and Population Health Sciences Director, Wisconsin Alzheimer’s.
ANDREA LD ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled.
Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
1 IRIS Initiative to Reduce the Impact of Schizophrenia DON’T DELAY! IT’S TIME TO REDUCE THE IMPACT OF PSYCHOSIS IN YOUNG PEOPLE……. NOW!
Cognitive Responses and Organic Mental Disorders
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Alzheimer's: An Investigation into Treatment Options Dana McGuire and Jessica Scharfenberg MPH 543: Leadership and Organizational Management Concordia.
How research helps people with dementia Tom Dening 24 th November 2015.
Dementia Research Update Cornwall Research Showcase Thursday 22 nd October 2015 Dr Stephen Pearson Consultant in Older Adult Psychiatry Devon Partnership.
Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia.
Prescribing in Dementia. Plan What to prescribe? When to prescribe? How to review? Who to review?
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised,
DR JOHAN SCHOEMAN ACTING CONSULTANT PSYCHIATRIST OLDER PEOPLE’S MENTAL HEALTH SERVICES (SOUTH BEDFORDSHIRE AND LUTON) Basics of Dementia.
ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California October, 2004 Slides.
Clinical Trials in Alzheimer’s Disease Paul S. Aisen, MD Professor, Department of Neurosciences, UCSD Director, Alzheimer’s Disease Cooperative Study ASENT.
Music therapy in moderate and severe dementia of Alzheimer’s type: a case-control study H.B. Svansdottir and J. Snaedal Geriatric Department, Landspitali.
Biomedical Research Centre for Mental Health and Dementia Unit at South London and Maudsley NHS Foundation Trust the Institute of Psychiatry, King’s College.
Emerging Treatments in Alzheimer’s Disease
Management of Geriatric Psychiatric Disorders Arash Mirabzadeh Psychiatrist University of Social Welfare and Rehabilitation Sciences.
Early Intervention in Dementia Bernie Coope Consultant Old Age Psychiatrist/Associate Medical Director/Honorary Senior Lecturer, Worcester Association.
Norton-scientificcollection.com/collection. HEALTH NEWS Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s.
Relapse Risk after Discontinuation of Risperidone in Alzheimer’s Disease Devanand et al NEMJ 2012; 367: By Hila Hoch, MD.
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Palliative Care Education Module
Alzheimer’s Disease (AD)
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial
Dr Gayan Perera Epidemiologist
Polypharmacy and specific medication profiles as predictors of treatment and health outcomes in dementia Dr Christoph Mueller, NIHR Academic Clinical Lecturer.
Modifying Disease Course in Alzheimer's Disease
The management of challenging behaviour in people with dementia
Early Dementia Distinguishing AD From MCI
Section III: Neurohormonal strategies in heart failure
11/30/2018 Using Delayed Start Design and Analysis to Investigate Potential Disease Modifying Effects in Alzheimer’s Disease.
Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias Dement.
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
Susan D. Rountree, Alireza Atri, Oscar L. Lopez, Rachelle S. Doody 
Presentation transcript:

Will we ever have effective treatments for dementia? Robert Howard King’s College London

The hubris of the Daily Express We beat dementia twice weekly

Objectives of presentation Review evidence for treatments for (i)cognitive symptoms and function (ii) behavioural symptoms and psychosis (iii) potential disease modification in AD Hope – 2 reasons to be optimistic about the future

What the evidence shows for cholinesterase inhibitor treatment of cognition and function Mild, moderate and severe AD – modest improvements in cognitive function and ADLs No effect on overall decline Withdrawal effect involving worsening cognition and function and earlier nursing home placement

Donepezil vs. placebo and MMSE score over 2 years in the AD2000 trial

Change in MMSE in first 12 weeks of AD2000 for Donepezil and Placebo

What happens when cholinesterase inhibitor therapy is stopped? The DOMINO trial

Nursing home placement in the DOMINO trial Kaplan-Meier survival curve

What the evidence shows for treatment of behavioural symptoms and psychosis Only risperidone is convincingly superior to placebo in treatment of agitation, aggression and psychosis in AD Psychosis returns when treatment stops Dementia drugs ineffective in AD

Pivotal risperidone trial data and the difficulties of evaluating treatment of behavioural symptoms

What happens when you stop an antipsychotic in an individual patient?

Dementia drugs no better than placebo in treatment of agitated behaviours in AD

Disease modification in AD. It should have been so easy……. The Hubris of Neuroscience

Results of the Rember trial sounded amazing, but the data were never published…

Disease modification in Alzheimer’s disease An elusive Holy Grail No shortage of translationally-identified targets Anti-amyloid (immunotherapy, anti-aggregation, γ- and β- secretase inhibitors) Neurotransmitter-based Metabolic and neurotrophic drugs Regenerative approaches Glial cell modulators Anti-tau proteinopathy The difficult truth is that everything (so far) has failed

Data from Phase 3 Bapineuzumab trials showed failure on primary outcome as usual

Hope 1. Almost all psychiatric treatments discovered through serendipity

Repurposing trials are perfect for NHS

Hope 2 – Adult hippocampal neurogenesis

In conclusion Current symptomatic treatments make modest but measurable differences to cognition and function Behavioural disturbance and psychosis have an evidence-based and licensed treatment Difficult to predict timetable for discovery of disease modifying drugs or lifestyle interventions with impact, but live in hope

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.